Urologic oncology, vol.38, 2020 (SCI-Expanded)
Article / Article
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE
Tc-99m MIBI scintigraphy, Renal mass, Benign vs. malignant, Oncocytoma vs. RCC, MDR pump, CELL CARCINOMA, ONCOCYTOMA, TC-99M-SESTAMIBI, DIFFERENTIATION, DIAGNOSIS, ACCURACY, SPECT/CT, FEATURES, TUMORS
Hacettepe University Affiliated:
Introduction: Despite the increasing accuracy of imaging modalities, the rate of benign renal tumors misclassified as malignant before surgery still non-negligible. Tc-99m sestamibi was demonstrated to be a possible reliable agent in discriminating oncocytoma from renal cell carcinoma (RCC). We aimed to study the efficacy of Tc-99m MIBI tumor scintigraphy in evaluating clinical T1 renal masses.